IP Library Granted Patent US 8,809,291
Granted Patent B2
US 8,809,291 · App. 13/252,148 · Granted Aug 19, 2014

Patent

Inventors: Pierre-Yves Desprez (Richmond, CA); Judith Campisi (Berkeley, CA)
Assignees: California Pacific Medical Center Research Institute; The Regents of the University of California
C12Q1/6876G01N33/57492C12Q2600/158C12Q1/6886C12Q2600/156G01N33/57407G01N33/5743G01N33/57434C12Q2600/106G01N33/57415
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,291
App. No.
13/252,148
Granted
Aug 19, 2014
Kind
B2
Abstract

A method for treatment of breast cancer and other types of cancer. The method comprises targeting and modulating Id-1 gene expression, if any, for the Id-1 gene, or gene products in breast or other epithelial cancers in a patient by delivering products that modulate Id-1 gene expression. When expressed, Id-1 gene is a prognostic indicator that cancer cells are invasive and metastatic.

Claims (9)

1. A method for treatment and amelioration of a cancer in breast, cervical, ovarian, endometrial, squamous cells, or prostate tissue or melanoma in a patient comprising the steps of:

a) providing a delivery vehicle comprising an antisense transcript which modulates Id-1 gene expression;

b) delivering said delivery vehicle to said patient; and

c) modulating Id-1 gene expression in said patient for treatment and amelioration of a cancer.

2. The method of claim 1 wherein said cancer is breast cancer.

3. The method of claim 1 wherein the delivery vehicle is an adenoviral, adeno-associated viral, lentis viral or retroviral vector, a cationic liposome, polycationic polymer or polyplex, a pharmaceutically acceptable composition, or a device which facilitates a delivery of such delivery vehicle.

4. The method of claim 1 wherein said cancer is prostate cancer.

5. The method of claim 3 wherein the delivery vehicle is a pharmaceutically acceptable composition.

6. The method of claim 1 wherein said delivering step is carried out intravenously, orally or by injection.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 21, 2012
From: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 028254/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: DESPREZ, PIERRE-YVES
To: CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE
Reel/Frame 027008/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: CAMPISI, JUDITH
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 027008/0628 →
Continuity (6)
Division 12326832 · Dec 2, 2008
Division 11390682 · Mar 27, 2006
Continuation 09952534 · Sep 14, 2001
Provisional Application 60232529 · Sep 14, 2000
Provisional Application 60232558 · Sep 14, 2000
Related Publication 20120021047A1 · Jan 26, 2012